Logo image of BCTX

BRIACELL THERAPEUTICS CORP (BCTX) Stock Fundamental Analysis

NASDAQ:BCTX - Nasdaq - CA1079301091 - Common Stock - Currency: USD

4.42  -0.65 (-12.82%)

Fundamental Rating

0

Overall BCTX gets a fundamental rating of 0 out of 10. We evaluated BCTX against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of BCTX have multiple concerns. BCTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCTX has reported negative net income.
In the past year BCTX has reported a negative cash flow from operations.
BCTX had negative earnings in each of the past 5 years.
BCTX had a negative operating cash flow in each of the past 5 years.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -81.59%, BCTX is not doing good in the industry: 69.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -81.59%
ROE N/A
ROIC N/A
ROA(3y)-73.12%
ROA(5y)-202.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

BCTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BCTX has more shares outstanding
BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

BCTX has an Altman-Z score of -36.30. This is a bad value and indicates that BCTX is not financially healthy and even has some risk of bankruptcy.
BCTX has a Altman-Z score of -36.30. This is amonst the worse of the industry: BCTX underperforms 92.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.3
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BCTX has a Current Ratio of 0.49. This is a bad value and indicates that BCTX is not financially healthy enough and could expect problems in meeting its short term obligations.
BCTX's Current ratio of 0.49 is on the low side compared to the rest of the industry. BCTX is outperformed by 93.43% of its industry peers.
A Quick Ratio of 0.49 indicates that BCTX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.49, BCTX is doing worse than 93.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

BCTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -186.13%.
EPS 1Y (TTM)-186.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-560%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-141.7%
EPS Next 2Y14.43%
EPS Next 3Y14.16%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

BCTX's earnings are expected to grow with 14.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y14.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (2/21/2025, 8:02:58 PM)

4.42

-0.65 (-12.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-16 2024-12-16/amc
Earnings (Next)06-12 2025-06-12
Inst Owners5.16%
Inst Owner Change15.24%
Ins Owners0.78%
Ins Owner Change0%
Market Cap13.04M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.24%
Min EPS beat(2)86.67%
Max EPS beat(2)119.8%
EPS beat(4)2
Avg EPS beat(4)-55.01%
Min EPS beat(4)-251.48%
Max EPS beat(4)119.8%
EPS beat(8)5
Avg EPS beat(8)-22.46%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-300%
EPS NQ rev (3m)-300%
EPS NY rev (1m)-459.24%
EPS NY rev (3m)-459.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.95
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-8.33
FCFYN/A
OCF(TTM)-8.18
OCFYN/A
SpS0
BVpS-0.81
TBVpS-0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.12%
ROA(5y)-202.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 544.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -36.3
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-186.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-560%
EPS Next Y-141.7%
EPS Next 2Y14.43%
EPS Next 3Y14.16%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.61%
OCF growth 3YN/A
OCF growth 5YN/A